Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Free Cash Flow (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Free Cash Flow for 2 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 90.74% to -$6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.3 million, a 70.37% increase, with the full-year FY2025 number at $100000.0, up 100.68% from a year prior.
  • Free Cash Flow was -$6.4 million for Q4 2025 at Neuphoria Therapeutics, down from -$3.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $11.5 million in Q1 2025 to a low of -$6.4 million in Q4 2025.